Wells Fargo Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $980
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Overweight rating on Regeneron Pharmaceuticals and raised the price target from $875 to $980.
August 21, 2023 | 2:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals' price target has been raised from $875 to $980 by Wells Fargo, maintaining an Overweight rating.
The raised price target and maintained Overweight rating by Wells Fargo indicates a positive outlook for Regeneron Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100